Results 131 to 140 of about 10,008,274 (374)

Follicle-Stimulating Hormone Biological Products: Does Potency Predict Clinical Efficacy? [PDF]

Int J Mol Sci, 2023
Lispi M, Humaidan P, Bousfield GR, D'Hooghe T, Ulloa-Aguirre A.   +4 more
europepmc   +1 more source

Cyclic nucleotide signaling as a drug target in retinitis pigmentosa

FEBS Letters, EarlyView.
Disruptions in cGMP and cAMP signaling can contribute to retinal dysfunction and photoreceptor loss in retinitis pigmentosa. This perspective examines the mechanisms and evaluates emerging evidence on targeting these pathways as a potential therapeutic strategy to slow or prevent retinal degeneration.
Katri Vainionpää, Ahmed B. Montaser, Henri Leinonen   +2 more
wiley   +1 more source

Determining and Accounting of Fair Value in Agricultural Activities [PDF]

, 2012
Biological assets and agricultural products bring about the subject of agricultural production. Having biological transformation of biological assets and agricultural products via the cases such as growth, reproduction, deterioration, decay; makes the ...
Ahmet GÖKGÖZ
core  

Initial prescriptions and medication switches of biological products: an analysis of prescription pathways and determinants in the Swiss healthcare setting. [PDF]

BMJ Open, 2023
Wirth K, Boes S, Näpflin M, Huber C, Blozik E.   +4 more
europepmc   +1 more source

TRAF2 binds to TIFA via a novel motif and contributes to its autophagic degradation

FEBS Letters, EarlyView.
TRAF family members couple receptor signalling complexes to downstream outputs, but how they interact with these complexes is not always clear. Here, we show that during ADP‐heptose signalling, TRAF2 binding to TIFA requires two short sequence motifs in the C‐terminal tail of TIFA, which are distinct from the TRAF6 binding motif.
Tom Snelling, Kodi Hunter, Celest W. S. Tay, Nicola T. Wood, Philip Cohen   +4 more
wiley   +1 more source

Next-Generation Sequencing: A Promising Tool for Vaccines and Other Biological Products. [PDF]

Vaccines (Basel), 2023
Nellimarla S, Kesanakurti P.
europepmc   +1 more source

The epithelial barrier theory proposes a comprehensive explanation for the origins of allergic and other chronic noncommunicable diseases

FEBS Letters, EarlyView.
Exposure to common noxious agents (1), including allergens, pollutants, and micro‐nanoplastics, can cause epithelial barrier damage (2) in our body's protective linings. This may trigger an immune response to our microbiome (3). The epithelial barrier theory explains how this process can lead to chronic noncommunicable diseases (4) affecting organs ...
Can Zeyneloglu, Huseyn Babayev, Ismail Ogulur, Sena Ardicli, Yagiz Pat, Duygu Yazici, Bingjie Zhao, Lihong Chang, Xiaoqing Liu, Paolo D'Avino, Manru Li, Ceren Biçer, Fatma Hacer Kurtoğlu Babayev, Raja Dhir, Kari C. Nadeau, Marie‐Charlotte Brüggen, Mubeccel Akdis, Cezmi A. Akdis   +17 more
wiley   +1 more source

Utilization of the wastes of vital activity [PDF]

The recycling of wastes from the biological complex for use in life-support systems is discussed. Topics include laboratory equipment, heat treatment of waste materials, mineralization of waste products, methods for production of ammonium hydroxide and ...
Chizhov, S. V., Drigo, Y. A., Farafonov, N. S., Gusarov, B. G., Novikov, V. M., Samsonov, N. M., Yazdovskiy, V. I.   +6 more
core   +1 more source

REQUIREMENTS ON CLINICAL TRIALS FOR VETERINARY PHARMACEUTICAL PRODUCTS FOR FISH [PDF]

Medicamentul Veterinar, 2016
Veterinary pharmaceutical products intended for use in fish should comply with all usual requirements regarding approval for marketing, according to the Order of the President of the National Sanitary Veterinary Agency and for Food Safety No.187/2007 ...
Simona Sturzu, Alina Draghici, Daniela Tirsinoaga, Mariana Dumitrache, Cristina Popica, Andreea Maftei   +5 more
doaj  

Biological products from the point of view of the pharmacist**Read before Scientific Section, A. Ph. A., Indianapolis meeting, 1917. [PDF]

, 1917
L.E. Sayre
openalex   +1 more source